Human Serum for Diagnostics & IVD — Selection Guide for Calibrators and Controls

In diagnostic assay development, the serum matrix is not a background material — it is an active component that directly determines assay performance. Selecting the wrong serum type, lot or serology profile can invalidate months of development work.

Why the Serum Matrix Matters in Diagnostics

IVD assays measure analytes in human serum or plasma. Calibrators and controls must use a matrix that closely approximates the clinical samples being tested. Using BSA in buffer as a matrix alternative creates a matrix effect — the signal response differs from real serum because of differences in protein concentration, viscosity, pH buffering capacity and non-specific binding characteristics.

For regulatory submissions under the EU IVDR (In Vitro Diagnostic Regulation), matrix matching between calibrators, controls and clinical samples is a documented quality requirement.

Key Serum Types for Diagnostics Applications

Universal Negative Human Serum: The Foundation of IVD Development

Universal Negative Serum is the standard starting material for IVD assay development. It is screened and confirmed negative for:

• HIV 1 and 2 (antibody and p24 antigen)
• Hepatitis B surface antigen (HBsAg)
• Hepatitis C antibody (anti-HCV)
• Syphilis (Treponema pallidum antibody)
• HTLV I/II (in some specifications)

This screening profile defines a "clean" human serum matrix with no interfering analytes for the listed pathogens. It is the baseline upon which positive controls are spiked to defined concentrations for calibrator preparation.

Lot-to-Lot Consistency: The Diagnostics Challenge

Unlike cell culture applications where a single validated lot can be reserved for a project, IVD manufacturers often need consistent serum supply over multi-year product lifecycles. This creates a specific challenge: how do you maintain assay performance when serum lots inevitably change?

Best practices for managing lot transitions in diagnostics:

• Run parallelism studies: test new lots against your assay reference panel before qualifying them for production use
• Bridge lots with overlap: maintain sufficient supply of the validated lot to run parallel production while qualifying the new lot
• Define acceptance criteria upfront: establish quantitative performance thresholds before starting lot qualification, not after
• Reserve strategic quantities: calculate based on assay shelf life × production volume, not just immediate needs

Matrix Effects and How to Detect Them

A matrix effect occurs when components of the serum matrix other than the target analyte affect the assay signal. Common sources include lipids (lipemia), high IgG concentrations, heterophilic antibodies and rheumatoid factor. For assay development, testing for matrix effects requires:

• Dilution linearity: spike analyte at multiple concentrations and verify proportional recovery
• Recovery studies: compare spiked serum signal to buffer-based standard
• Interference testing: test with lipemic, haemolysed and icteric matrix variants

Human Plasma vs. Human Serum in Diagnostics

Serum and plasma differ primarily in the presence of fibrinogen and clotting factors in plasma. For most immunoassays, serum is the preferred matrix because it avoids fibrin interference and is closer to the clinical testing matrix. Plasma is preferred for coagulation assays and applications where rapid sample processing is required. Confirm which matrix your clinical samples use before selecting your calibrator format.